Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer

Anticancer Research

Volumn 21, Issue 2 B, 2001, Pages 1367-1370

  De Rosa, L ^a   Lalle, M ^a   Perillo, A ^a   Pierelli, L ^a   Salerno, M G ^a   Cortesi, E ^a   Martelli, O ^a   Pandolfi, A ^a   Amodeo, R ^a   Marzetti, L ^a   Mancuso, S ^a   Scambia, G ^a  

^a Circ Gianicolense   (Italy)

Author keywords

Breast cancer; Docetaxel; Epirubicin; High dose chemotherapy

Indexed keywords

DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANEMIA; APHERESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN CELL; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0035017815     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
2. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
3. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five year results
4. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell trasnplantation for metastatic breast cancer
5. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
6. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer
7. Chemotherapy for metastatic disease
8. Drugs ten years later: Epirubicin
9. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
10. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclin-containing chemotherapy
11. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
12. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
13. Epirubicin + G-CSF as peipheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients
14. Docetaxel and filgrastim provides a safe and effective mobilization regimen prior to high-dose chemotherapy for breast cancer
15. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: Results of a randomized comparison
16. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: Non hematological, haematological toxicities and role of growth factor administration
17. Reporting results of cancer research
18. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
19. Taxoids in combination with epirubicin: The search for improved outcomes in breast cancer
20. An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen
21. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy
22. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma
23. 2 of CY
24. Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer